The treatment of chronic hepatitis B: Focus on adefovir-like antivirals

Abstract

Several options for the treatment of hepatitis B have been licensed in the last years: interferon, pegylated interferon, lamivudine, adefovir, entecavir, and telbivudine. In addition tenofovir has been licensed in the EU and is expected to be licensed in the USA in 2008. The antivirals can be divided into “lamivudine-like” and “adefovir-like”, which clinically differ in their capacity to induce “YMDD” mutants, which are the hallmark of lamivudine resistance. The differing resistance profile makes them good combination partners, even in the absence of synergy in antiviral potency.

Keywords:

• adefovir
• tenofovir
• pradefovir
• almefovir
• antiviral therapy
• hepatitis B

Disclosure

The author reports no conflicts of interest.